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doi:10.1016/j.jtcvs.2004.02.017254 The Journal of Thoracic and CardioObjective: Screening for lung cancer with computed tomography may detect cancers
at an earlier stage but may also result in overdiagnosis. We reviewed the thoracic
surgical operations performed on patients enrolled in our computed tomographic
screening program.
Methods: From January 1999 through December 2002, screening computed tomog-
raphy for lung cancer was performed annually on 1520 participants. All participants
were at least 50 years old and smoked more than 20 pack/y. We found 3130
indeterminate pulmonary nodules in 1112 participants (73%). Fifty-five participants
(3.6%) underwent 60 thoracic operations for a variety of indications. The medical
records of these 55 patients were reviewed.
Results: Indications for operation included suspicious pulmonary nodules, medias-
tinal adenopathy, and a spontaneous pneumothorax. Operations performed included
a lobectomy in 37 cases, wedge resection in 11, segmentectomy in 6, video-assisted
thoracoscopic surgical talc pleurodesis in 1, bilobectomy in 2, mediastinoscopy in 2,
and anterior mediastinotomy in 1. Benign disease was found in 10 patients (18.1%),
and lung cancer was found in 45 (81.9%), 2 of whom had metachronous lung
cancers. Cell types were adenocarcinoma in 15 cancers, bronchioloalveolar cell
carcinoma in 13, squamous cell in 13, carcinoid in 2, small cell in 2, and large cell
and undifferentiated non–small cell in 1 case each. Twenty-eight cancers were
classified as stage IA, 4 as IB, 4 as IIA, 1 as IIB, 4 as IIIA, 3 as IIIB, 1 as IV, and
2 as limited small cell carcinoma. Complications occurred in 27% of patients.
Operative mortality was 1.7%.
Conclusion: Computed tomographic screening finds a large number of indeterminate
pulmonary nodules in smokers 50 years old or older, most of which are observed and
not operated on. Although 47 cancers were detected thus far in this highly selected group
of patients, this represents only 1.5% of the pulmonary nodules identified.
vascular Surgery ● August 2004
Crestanello et al General Thoracic Surgery
G
TSLung cancer is the most common fatal malig-nancy in both men and women and is usuallydiagnosed at an advanced stage. Fewer than25% of the patients have localized diseasethat is potentially curable by surgical resec-tion at the time of diagnosis.1 Previous at-
tempts to screen large populations of high-risk patients for
early lung cancer with chest radiographs and sputum cyto-
logic examination have not decreased mortality from this
disease.2-6 Recently, low-dose chest computed tomographic
(CT) screening has been shown to detect lung cancer at an
earlier stage and thus may have an impact on lung cancer
mortality.7-9 In 1999, the Mayo Clinic in Rochester, Min-
nesota, enrolled 1520 participants who underwent low-dose
spiral CT screening. All participants were symptom-free
men and women 50 years old or older who had a 20
pack-year history of smoking within the previous 10 years.
The prevalences of lung cancer and pulmonary nodule find-
ings and the 1- and 2-year incidences of findings from our
institution have previously been reported.10,11 Little infor-
mation, however, is available about the type and number of
thoracic surgical procedures that occur as a result of CT
screening. The purpose of this report is to update our
incidence findings and to review our early operative expe-
rience after CT screening for lung cancer.
Methods
The protocol for all participants in the Mayo Clinic low-dose spiral
CT screening program for lung cancer has previously been re-
ported elsewhere.10,11 One thousand five hundred twenty partici-
pants underwent a baseline prevalence CT examination and three
subsequent annual incidence examinations. The medical records of
those participants who underwent a thoracic surgical procedure
were reviewed for surgical indications, preoperative evaluation,
surgical procedure, pathologic diagnosis, perioperative morbidity
and mortality, and follow-up. Operative mortality included all
patients who died within 30 days of operation and those patients
who died later but during the same hospitalization. This study was
approved by the Mayo Foundation institutional review board.
Informed consent was obtained in all cases.
Results
As of November 2002, a total of 3130 indeterminate pul-
monary nodules had been identified in 1112 (73%) of the
1520 participants (Table 1). Further evaluation of these
nodules was obtained at the discretion of the participants’
individual physicians. Additional studies most commonly
obtained included thin-section chest CT, nodule-enhance-
ment CT, positron-emission tomography (PET), and occa-
sionally, bronchoscopy and transthoracic needle aspiration.
Sixty thoracic surgical procedures were performed on 55
participants (33 women and 22 men). Age was a median of
62 years and ranged from 52 to 80 years. Fifty patients
underwent a single procedure and 5 underwent two. Indi-
The Journal of Thoracication for the initial procedure was a pulmonary nodule with
a high index of suspicion for cancer in 53 patients, medi-
astinal adenopathy in 1, and spontaneous pneumothorax in
1. Specific indications for pulmonary nodule resection in-
cluded nodule enlargement on serial CTs in 32 patients, a
new nodule in 12, nodule enhancement in 5, and morpho-
logic appearance worrisome for malignancy in 4 (Table 2).
The number of pulmonary nodules detected by CT in
these 53 patients ranged from 1 to 7 (median 3). A single
nodule was observed in 15 patients, 2 nodules were ob-
served in 7, 3 nodules were observed in 6, 4 nodules were
observed in 11, 5 nodules were observed in 8, 6 nodules
were observed in 5, and 7 nodules were observed in 1.
These nodules were followed up for a median of 4.3 months
before surgical intervention (range 21 days–31 months).
Preoperative evaluation included thin-section CT in 25
cases (13 patients had 1 examination, 8 had 2, 3 had 3, and
1 had 4), CT nodule enhancement in 14 cases (13 patients
had 1 examination and 1 had 2), and PET scan in 16 cases.
Preoperative bronchoscopy was performed in 5 patients.
Results were normal in 3 cases and identified an endobron-
chial squamous cell carcinoma in 2 patients. Transthoracic
needle aspiration was done in 5 patients; it demonstrated
lung cancer in 4 cases and was nondiagnostic in the other.
The surgical procedure was performed in the 53 patients
with a pulmonary nodule after the prevalence CT in 22
patients, after the first annual incidence CT in 9, after the
second annual incidence CT in 15, and after the third annual
incidence CT in 7. The procedures performed on these 53
patients are shown in Table 3. The 44 patients with lung
cancer underwent a lobectomy in 35 cases, bilobectomy in
2, segmentectomy in 3, and wedge resection in 4. The
limited resections were performed because of poor pulmo-
TABLE 1. Pulmonary nodules found on screening CT
Participants Nodules
Baseline CT 1520 1646
First annual incidence CT 1478 837
Second annual incidence CT 1441 382
Third annual incidence CT 1358 265
Total 3130
TABLE 2. Indication for initial surgical procedure
Indication No. of patients
Enlarging nodule 32
New incidence of nodule 12
Positive CT nodule enhancement 5
Morphologic appearance worrisome for cancer 4
Enlarged mediastinal lymph nodes 1
Spontaneous pneumothorax 1nary function in 6 cases and for advanced stage disease in 1.
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mediastinal lymphadenectomy, 19 had preliminary video-
assisted thoracoscopic surgery (VATS), and 3 had prelimi-
nary mediastinoscopy. The 9 patients with benign pulmo-
nary nodules all underwent a limited pulmonary resection,
except 1 who underwent a lobectomy for a centrally located
nodule that was not amenable to wedge excision. These
resections were performed through a thoracotomy in 6 cases
and by VATS in 3 cases.
Lymph node enlargement in the single patient with me-
diastinal adenopathy was detected after the third annual
incidence CT and this patient underwent a left anterior
mediastinotomy that demonstrated metastatic pulmonary
TABLE 3. Initial operations performed for pulmonary nod-
ules
Operation type No. of patients
Lobectomy 36
Right upper 9
Right middle 3
Right lower 8
Left upper 10
Left lower 6
Bilobectomy 2
Segmentectomy 6
Wedge resection 9
Single wedge resection 7
Multiple wedge resections 2
TABLE 4. Diameters of pulmonary nodules resected
Diameter (cm) Malignant nodules Benign nodules* Total nodules
0.5 2 7 9
0.6–1 17 11 28
1.1–2 24 5 29
2.1–3 3 1 4
3.1–4 1 0 1
4 1 0 1
*No size data were available for 7 benign nodules.
TABLE 5. Diameters of malignant pulmonary nodules
Stage of carcinoma
Size of nodule
(cm, median and range)
IA 1.1 (0.5–3.0)
IB 1.1 (0.7–2.0)
IIA 1.5 (1.0–1.8)
IIB 6.0*
IIIA 2.4 (1.3–3.5)
IIIB 1.5 (1.0–1.6)
IV 1.2*
*Only 1 patient.adenocarcinoma. The single patient with a spontaneous
256 The Journal of Thoracic and Cardiovascular Surgery ● Augupneumothorax had it diagnosed between the prevalence and
first annual incidence CTs and underwent bilateral bleb
resections with pleurodesis by VATS.
Postoperative complications occurred in 27% of cases
and included prolonged air leak in 6 patients, atrial arrhyth-
mias in 4, pneumonia in 4, and ileus, cerebral vascular
accident, depression, and temporary vocal cord paralysis in
1 each. There was 1 operative death (operative mortality
1.7%) from an intracerebral hemorrhage 14 days after a left
lower lobectomy for a stage IIIA (T3 N1 M0) adenocarci-
noma.
Seventy-nine pulmonary nodules (31 benign and 48 ma-
lignant) were resected in the 53 patients whose indication
for operation was a suspicious pulmonary nodule. A single
nodule was resected in 33 patients, 2 were resected in 15, 3
were resected in 4, and 4 were resected in 1. The diameters
of the resected nodules are described in Tables 4 and 5. Nine
patients had only benign nodules resected; the remaining 44
all had lung cancer. Cancer cell types in these 44 patients
were squamous cell in 13 patients, adenocarcinoma in 13,
bronchioloalveolar cell in 13, carcinoid in 2, small cell in 2,
and large cell in 1 (Table 6). Twenty-seven patients had
disease classified as stage IA, 3 as IB, 4 as IIA, 1 as IIB, 3
as IIIA, 3 as IIIB, and 1 as IV. In the group of 7 patients
with advanced stage cancer (IIIA, IIIB, or IV), 3 had their
cancer operated on within 2 months of detection on screen-
ing CT and 4 were observed for a median of 18.2 months
(range 6-26.8 months) before resection. The 2 patients with
small cell carcinoma had disease classified as limited small
cell carcinoma. The T classifications in patients with non–
small cell carcinoma were T1 in 33 cases, T2 in 4, T3 in 1,
and T4 in 4. The N classifications were N0 in 32 cases, N1
TABLE 6. Pathologic classification of resected pulmonary
nodules
Pathologic type No. of nodules
Benign nodules 31
Granuloma 12
Intrapulmonary lymph node 5
Lung scar or fibrosis 4
Bleb or bullae 3
Pneumocystic hyperplasia 2
Visceral pleural thickening 2
Hamartoma 1
Pulmonary embolism 1
Bronchoalveolar cell hyperplasia 1
Malignant nodules 48
Squamous cell carcinoma 15
Bronchoalveolar carcinoma 15
Adenocarcinoma 12
Carcinoid 3
Small cell carcinoma 2
Large cell carcinoma 1in 8, and N2 in 2.
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ranged from 0.1 to 41 months (median, 19 months). Five
patients have died, all from lung cancer. Forty-nine patients
are currently alive, 3 with recurrent lung cancer. The initial
site of recurrent cancer was locoregional in 2 cases, sys-
temic in 2 cases, and both in 4 cases.
Five patients had a subsequent thoracic operation. One
patient initially had a left lower lobectomy for a T2 N0 M0
adenocarcinoma with bronchioloalveolar features and un-
derwent a subsequent right upper lobectomy for a T2 N0
M0 adenocarcinoma 11 months later. This patient is cur-
rently alive with no evidence of disease 14 months after the
second operation. Two patients had mediastinal lymphade-
nopathy develop 6 and 12 months after curative pulmonary
resection for stage IA and IIA lung cancer, respectively.
Mediastinoscopy revealed recurrent cancer in both patients.
Both were treated with radiation and chemotherapy and are
alive 25 and 41 months after the initial resection, respec-
tively. The fourth patient had a right middle lobectomy for
stage IA typical carcinoid and underwent a right upper lobe
wedge resection for an undifferentiated non–small cell car-
cinoma (T1 N0 M0) 22 months later. This patient died of
disseminated non–small cell carcinoma 11 months after the
second operation. The fifth patient had a malignant pleural
effusion develop 10 months after wedge resection for ex-
tensive stage IIIA adenocarcinoma. A VATS talc pleurode-
sis was performed, and this patient died 5 months after the
original surgery.
Discussion
Screening a high-risk population for lung cancer with low-
dose spiral CT results in the detection of multiple pulmo-
nary nodules, most of which are benign.7-11 Management of
these nodules poses significant diagnostic and therapeutic
challenges, and few guidelines have emerged as to how
these patients should be evaluated.12,13 Options available
include either further evaluation at the time of discovery
with thin-section CT, CT enhancement, PET scan, biopsy
(transbronchial or transthoracic), VATS resection, and tho-
racotomy or surveillance with high-resolution CT every 3 to
6 months. Evaluation and management of the individual
participant after detection of the pulmonary nodule were not
part of our CT screening trial protocol. Instead, all patients
were subsequently evaluated by their personal physicians
with a combination of the management options mentioned
here.
In our experience, the small diameter of most of these
pulmonary nodules limits the usefulness of some diagnostic
imaging modalities. Imaging with PET or CT enhancement
is limited to nodules that are 1 cm or more in diameter.14
This size limitation would exclude 25% of all nodules and
16% of the malignant nodules found in our series from
noninvasive evaluation. Invasive diagnostic procedures,
The Journal of Thoraciwhether by needle aspiration, bronchoscopy, or VATS, are
also limited by both the size of the nodule and the anatomic
location.15,16 Preoperative localization with methylene blue
injection and wire placement may be of some value in
patients considered for VATS or thoracotomy.16,17 In our
series, preoperative CT wire localization was used in 2
cases. With this stepwise, gradual approach, the number of
explorations for benign disease was minimized to fewer
than 1% of the participants.
Controversy exists regarding the extent of pulmonary
resection necessary for cure and the need for lymphadenec-
tomy in these small cancers.18-20 Formal resection of the
tumor by lobectomy and complete mediastinal lymphade-
nectomy has been the standard of care practiced by most
thoracic surgeons.21 Limited resection, in contrast, appears
to increase local recurrence and may compromise surviv-
al.22,23 Also, in one series 7% of patients with lung cancers
smaller than 1 cm in diameter were demonstrated to have
N1 or N2 lymph node metastases.24 In our series 15.7% of
patients with lung cancer 1 cm or less in diameter had N1
lymph node involvement. Currently, few data are available
to indicate the effect of limited pulmonary resection on
survival and local recurrence with these small cancers.22,23
Thus we continue to recommend a formal anatomic pulmo-
nary resection with mediastinal lymphadenectomy for pa-
tients with lung cancer of any size who otherwise are in
good health. A randomized trial comparing these two op-
tions is necessary to determine the proper treatment of small
lung cancers.
CT screening results in the detection of smaller pulmo-
nary nodules than those detected by screening chest radiog-
raphy.7 Some of these nodules are, of course, malignant.
Whether earlier detection of lung cancer by CT screening
will alter the natural history of this disease has not yet been
determined. However, reported survival rates of 80% after
pulmonary resection for stage IA lung cancer detected by
CT are encouraging.25 Follow-up in our series is too short to
evaluate of the impact of CT screening on survival. Some
authors are doubtful of a survival benefit because of the
tendency of some lung cancers to metastasize even at an
apparently localized stage.26,27 Currently, there is no proof
that CT screening will improve overall mortality from lung
cancer.
Unfortunately, CT screening also detects advanced can-
cers. Eight of our patients who had surgery were at stage
IIIA or higher, and there were 3 other participants with
advanced cancer in our CT screening trial who did not
undergo any surgical intervention. These advanced cancers,
as well as some of the small cell cancers detected, suggest
that CT screening may not have as significant an impact on
mortality as initially suggested. We await the findings of the
National Lung Cancer Screening Trial by the American
c and Cardiovascular Surgery ● Volume 128, Number 2 257
General Thoracic Surgery Crestanello et al
G
TSCollege of Radiology Imaging Network that is currently
underway.
Mortality associated with surgical resection was low
(1.7%), and fortunately no deaths occurred among the pa-
tients found to have only benign disease. Morbidity was
significant, indicating that pulmonary resection should not
be undertaken lightly. For the present, careful patient selec-
tion and surgical judgment are critical in determining who
should undergo surgical intervention. Observing small, po-
tential curable lung cancers may allow cells to metastasize,
negating the value of CT screening. Conversely, if too many
benign nodules are resected, patients and their physicians
will not want to consider CT screening. Perhaps in the
future an appropriate percentage of “negative” or benign
pulmonary resections will be established
In conclusion, low-dose CT screening for lung cancer
detects a large number of indeterminate pulmonary nodules.
Although most of these nodules are benign, a significant
number of early lung cancers are detected in this selected
group of patients. Although the mortality associated with
surgery in these patients is low, careful patient selection is
necessary to avoid the performance of unnecessary proce-
dures for benign disease. Whether early detection of lung
cancer by CT screening followed by pulmonary resection
decreases cancer mortality remains unknown.
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Discussion
Dr John D. Mitchell (Denver, Colo). Epidemiologists will tell you
that for a screening test implemented on a large scale to be
effective, it must provide benefit to the targeted population, usually
through improved survival with respect to the disease in question.
At the same time, the screening process should not impose undue
harm on the population by way of numerous false-positive results
or needless follow-up tests, nor should it place a disproportionate
burden on society, typically through excessive costs. Low-dose CT
is the most promising technology used to date to screen for lung
cancer in high-risk populations, although questions persist regard-
ing actual survival benefit, the so-called overdiagnosis of indolent
tumors, and cost.
What epidemiologists do not tell you is what to do with all
those tiny nodules identified on the scans. In this report Crestanello
and colleagues have described their surgical experience associated
with the lung cancer screening trial with CT at the Mayo Clinic.
The management of these patients, with aggressive intervention in
those with malignancy and minimization of invasive procedures in
those with a benign process, is of practical importance to all
thoracic surgeons. I have three questions for Dr Crestanello.
st 2004
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TSFirst, I wonder if you could discuss in greater detail from your
experience with this study how these patients with a positive
screening result should be evaluated. I do not mean someone with
an obvious 3-cm cancer, but patients with much smaller nodules,
perhaps less than 1 cm, where PET may not be helpful, or patients
with multiple nodules. When should these patients be observed,
and when should intervention be pursued? Have you and your
colleagues devised an evaluation strategy or treatment algorithm
on the basis of your findings?
Dr Crestanello. Yes, we have an algorithm recommended for
patients found to have nodules on the CT. It is basically based on
the size of the nodules, on the aspects of the nodules. For nodules
smaller than 4 mm in diameter, it is recommended that the patient
have a thin-section CT in 6 months. For nodules in which the
diameter is between 4 and 8 mm, thin-section CT is recommended
in 3 months. For nodules between 8 and 20 mm, thin-section CT
or a nodule-enhancement CT study or a PET scan is recommended
immediately. And obviously, for nodules that are bigger than 20
mm in diameter, a biopsy, surgical or transthoracic, is recom-
mended. So how do you interpret the results of the further studies?
Well, if there is any enlargement of the nodules in the subsequent
studies, a surgical biopsy is recommended, as is the case if the CT
enhancement study or PET results are positive.
Dr Mitchell. Second, in many CT screening studies, the per-
centage of stage IA cancers is often quite high, between 80% and
90%. In this study, although still high, the percentage was more
around 60%. Why do you think you and your colleagues found
fewer early stage tumors or, to put it another way, a higher
percentage of more advanced tumors?
Dr Crestanello. That is an interesting question that also puz-
zled us. We compared our study with the other two large studies,
which are the studies from Japan7 and New York.8,25 The cancers
that they found, in the first study 15 in 3000 patients and in the
second study 27 in 1000 patients, were IA disease in 81% and 85%
of cases, respectively. Ours was 59%. The populations were dif-
ferent. One was in Japan, the other was in New York, and ours was
in the Midwest. Also, the criteria for enrollment in the trial wereThe Journal of ThoraciIn our study it was 50 years or older. The smoking criteria were
also different. Ours was greater than 20 packs/y and theirs was
greater than 10 packs/y. Also, the incidences of cancer in the New
York study and our study were different. There were 27 cancers in
1000 patients in their study, and in our study there were 54 cancers
in 1500 patients. We believe that all those factors may have
contributed to this difference in the incidence of early stage can-
cers.
Dr Mitchell. Finally, although CT is quite good at identifying
abnormalities, it is possible to miss tumors through CT screening.
Were there any cases like this in your series in which a patient
enrolled in the study had symptoms from lung cancer that was
missed by the screening?
Dr Crestanello. No, there were no such cases of which I am
aware. There was 1 patient who had cancer diagnosed on the basis
of sputum cytologic examination who was enrolled in the CT
scanning trial. The patient had a small cell cancer and was not
operated on and is not included in this series.
Dr Douglas Wood (Seattle, Wash). I want to follow up Dr
Mitchell’s last question regarding a more advanced cancer that
showed up because of symptoms. Have you looked at this in your
data? Dr Mitchell rightly pointed out the most compelling aspect,
which is the problem of screening false-positives, but one of the
other aspects is this problem of missed cancers. You only operated
on 2% of nodules, or even less than that, and the question is
whether there were nodules that on follow-up 4 months later or 6
months later or a year later you found to be cancers and in
retrospect wished you had operated on.
Dr Crestanello. Yes, there were some cases like that. In the CT
scanning trial there were nodules that were not initially identified
on the scan, and then in retrospect after reviewing the scan after the
first or the second annual incidence the scan was done, they were
identified in that situation. But they were all small nodules, and I
do not think that early operation on those patients would have
made a difference in the prognosis of these patients. There were no
big nodules that were missed. Those nodules that were diagnosed
in retrospect after a nodule appeared on subsequent scans were alldifferent. In the trial in New York, the age was 60 years or older. small nodules, in the 4-mm range or smaller.c and Cardiovascular Surgery ● Volume 128, Number 2 259
